Loading...
Loading...
Pieris AG and The Sanofi Group have jointly agreed to expand their
ongoing discovery and development partnership to include a novel
multispecific Anticalin® program. Under the existing
framework of the 2010 agreement, the new program will entitle Pieris to
an upfront payment from Sanofi and committed research funding as well as
payments for the achievement of research, preclinical, regulatory and
commercial milestones. Specific financial terms were not disclosed.
“Following more than two years of successful collaboration in this
multi-program agreement, the expansion demonstrates that the Anticalin
technology can deliver key differentiation over conventional biologic
approaches, including the development of multispecific targeted
therapeutics,” said Stephen Yoder, CEO of Pieris. “Sanofi and Pieris
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in